Cardiovascular genomics research has identified many genetic variants associated with cardiac conditions. Studies have shown that most causative gene variants are unique familial variants,1 and therefore, seen infrequently.2 Additionally, small panels used in clinical testing can miss causal gene variants implicated in inherited heart diseases.
Comprehensive next-generation sequencing (NGS) panels for cardiovascular genomics provide broad coverage of cardiac genes with known disease implications. Unlike single-gene assays or small panels, which lead to time-consuming and expensive iterative testing, NGS panels assess multiple cardiac genes simultaneously.
Join Dr. Amit V. Khera as he discusses how understanding genetic variation can be used to improve clinical care in cardiovascular disease and other important diseases. This webinar discusses the contribution of rare pathogenic variants to sudden cardiac death and cardiovascular disease, polygenic risk scores, and implications for clinical medicine.View Webinar
Researchers at the Montreal Heart Institute used Illumina microarrays to identify responder genotypes in a failed cholesterol drug trial.
Dr. Joshua Knowles discusses the importance of genetic cascade testing in familial hypercholesteremia, as well as implementing polygenic risk scores in clinical care.
Dr. Guillaume Paré discusses how genetics can help identify people at risk for familial hypercholesterolemia and early cardiovascular disease.
TruSight Cardio offers a single NGS-based solution for cardiomyopathy and cardiac gene research. It targets 174 genes with known associations to 17 inherited cardiac conditions.
TruSight Cardio covers 174 genes in a single workflow, reducing the cost of managing multiple assays.